Robotic-assisted versus open distal pancreatectomy for benign and low-grade malignant pancreatic tumors: a propensity score-matched study

Weng, Yiwu; Jin, Jiabin; Huo, Zhen; Shi, Yusheng; Yu, Jiang; Deng, Xiaxing; Peng, Chenghong; Shen, Baiyong

doi:10.1007/s00464-020-07639-9

Cited by 19 publications

(7 citation statements)

References 49 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OS for patients with benign or malignant IPMN (120 patients vs 54 patients) after robotic surgery (P < .001) addition, the postoperative bleeding rate was as low as 3.4%. Therefore, these results are similar to those of previous studies, 22,23 and indicate that robotic surgery for IPMN is feasible and safe. The ICG revised in 2017 15 described three factors as high-risk indicators, namely, obstructive jaundice, enlargement of a mural nodule to ≥5 mm, and a main pancreatic duct (MPD) ≥10 mm; and that any of these high-risk factors should be an absolute surgical indication.…”

Section: T a B L E 4 (Continued)supporting

confidence: 91%

Robotic pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: A large‐scale study

Zhang

Wang

et al. 2020

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

Background: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a mucin-producing tumor that develops from the epithelial lining of the main pancreatic duct or branch pancreatic ducts. Here, we assessed the feasibility and safety of various robotic pancreatectomy approaches to treating IPMN, and short-and longterm outcomes of robotic IPMN resection. Methods: Data from patients who underwent robotic pancreatectomy for IPMN between 2012 and 2019 at our hospital were retrospectively analyzed. The survival outcomes for patients were compared using the Kaplan-Meier method and Cox regression analysis. Results: Of the 174 patients who underwent robotic pancreatectomy, 120 and 54 patients had benign or malignant tumors, respectively. Patients with malignant IPMN had lost more weight in the 6 months prior to surgery (P = .008), and a higher serum level of CA19-9 (P < .001) and CEA (P < .001). Postoperative pancreatic or biliary fistula occurred in 17 or 6 patients overall, respectively. The pathology of the IPMN (P = .030), tumor diameter (P = .016), mural nodule (P = .023), tumor capsule (P = .003) and CA19-9 (P = .024) values were all independent risk factors for survival. The median OS time after surgical resection for the malignant IPMN group was 29.0 months (range, 21.6-36.4). The OS was significantly different in patients with IPMN according to their different pathology, tumor capsule, mural nodule group, CA19-9 level, or tumor diameter. Conclusions: This large-scale survey of 174 patients indicated that various robotic pancreatectomy approaches were feasible and safe for IPMN. Patients had an acceptable prognosis, indicating that robotic pancreatectomy represents a feasible potential therapeutic strategy for IPMN.

show abstract

Section: T a B L E 4 (Continued)supporting

confidence: 91%

Robotic pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: A large‐scale study

Zhang

Wang

et al. 2020

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

show abstract

“…Our centre employed open and minimally invasive surgical approaches, especially robot-assisted, to treat PmmRCC. Several studies regarding robotic-assisted versus open surgeries have been published to point out postoperative outcomes for typical pancreatic tumours in our centre (34,35). Our cohort also included cases of atypical excisions for malignant PmmRCC, such as enucleation; according to one study, these have similar effects to partial surgeries in T1 RCC (36).…”

Section: Comparison With Similar Researchmentioning

confidence: 99%

Outcomes following pancreatic metachronous metastatic renal cell carcinoma resection and comparisons with pancreatic neuroendocrine tumours

Shen

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The aim of this study was to investigate perioperative findings ofpancreatic metachronous metastatic renal cell carcinoma (PmmRCC) and pancreatic neuroendocrine tumours and long-term survival outcomes of PmmRCC in a high-volume single centre. Methods: The clinicopathological data of 29 PmmRCC patients treated in our centre from January 2013 to December 2021 were collected retrospectively. We analysed demographics, diagnoses, surgical information, 30-day morbidity data, and long-term survival outcomes. Preoperative characteristics and diagnosis were also compared with patients who had pancreatic neuroendocrine tumours during the same period in our centre. Results: PmmRCC patients were older (P < 0.001), less symptomatic (P = 0.017), more likely to appear hyper-vascular in imaging studies (P = 0.023), had more multiple nodules in the pancreas (P = 0.002), and had a larger tumour size (P = 0.046) than patients with pancreatic neuroendocrine tumours. No metastatic lymph nodes were detected, and 34.5% of PmmRCC cases were preoperatively misdiagnosed. At the last follow-up, 13 patients had tumour progression, and five died (two within 30 days postoperatively). Conclusions: Clinical characteristics and imaging results exhibited some differences between PmmRCC and pancreatic neuroendocrine tumours. Patients could benefit from PmmRCC surgery with an acceptable co-morbidity. No metastatic lymph nodes were found, even though suspected on imaging examination or detected intraoperatively. However, elucidating the surgical role and necessity of lymphadenectomy requires larger-sample studies.

show abstract

“…All patients underwent radical surgery for BTC. Patients were kept in spread-eagled position after general anesthesia, with the position adjusted based on the tumor type and location so as to facilitate surgery [8][9][10]. Patients in group A were treated with Oxo plus CDHP after surgery, and orally administered tegafur, gimeracil and oteracil potassium capsules (NMPA approval no.…”

Section: Patient Handlingmentioning

confidence: 99%

Effect of oteracil in combination with gimeracil on longterm survival and postoperative complications in elderly patients undergoing radical surgery for biliary tract cancer

Zhang¹,

Zhang²,

Wu³

et al. 2022

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the effect of oteracil (Oxo) in combination with gimeracil (CDHP) on long-term survival and postoperative complications in elderly patients undergoing radical surgery for biliary tract cancer (BTC).Methods: Clinical data for 70 patients who underwent radical surgery for BTC in the Oncology Department of the Changle People’s Hospital, Weifang, China from April 2017 to April 2018 were collected. The patients were equally assigned to group A and group B, based on odd or even hospitalization number. After surgery, patients in group A received the combination of Oxo and CDHP, while group B patients received gemcitabine only. Long-term survival and incidence of adverse reactions were compared.Results: Compared with group B, group A had higher total treatment effectiveness (p < 0.05), lower clinical indices (p < 0.05), lower BPI score (p < 0.001) and higher 3-year overall survival (p < 0.05).Conclusion: Combined use of oteracil and gimeracil significantly prolongs the survival time and reduce cancer pain in BTC patients, with minimal toxic and side effects. However, further clinical trials are required prior to application in clinical practice.

show abstract

Robotic-assisted versus open distal pancreatectomy for benign and low-grade malignant pancreatic tumors: a propensity score-matched study

Cited by 19 publications

References 49 publications

Robotic pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: A large‐scale study

Robotic pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: A large‐scale study

Outcomes following pancreatic metachronous metastatic renal cell carcinoma resection and comparisons with pancreatic neuroendocrine tumours

Effect of oteracil in combination with gimeracil on longterm survival and postoperative complications in elderly patients undergoing radical surgery for biliary tract cancer

Contact Info

Product

Resources

About